520,000 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Purchased by Elmind Capital LP

Elmind Capital LP bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, Holdings Channel reports. The institutional investor bought 520,000 shares of the biotechnology company’s stock, valued at approximately $5,200,000,000. BioCryst Pharmaceuticals comprises about 1.3% of Elmind Capital LP’s investment portfolio, making the stock its 19th largest holding.

Several other institutional investors have also recently made changes to their positions in BCRX. ADAR1 Capital Management LLC acquired a new position in BioCryst Pharmaceuticals in the second quarter valued at about $1,330,000. Hsbc Holdings PLC purchased a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at about $1,079,000. PDT Partners LLC purchased a new stake in BioCryst Pharmaceuticals during the second quarter worth about $245,000. Canada Pension Plan Investment Board purchased a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $1,158,000. Finally, Parkman Healthcare Partners LLC purchased a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $16,243,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $9.83 on Wednesday. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.56. The business’s 50 day simple moving average is $9.66 and its 200-day simple moving average is $9.00. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business’s revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.15 EPS. On average, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Wall Street Analyst Weigh In

BCRX has been the topic of several analyst reports. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Needham & Company LLC cut their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Citizens Jmp lifted their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Wedbush reduced their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a research note on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.